As you may have seen, Esperion scientists and collaborators recently published the definitive paper on the mechanism of action for bempedoic acid, “Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis,” in the journal Nature Communications. I sat down with authors and colleagues Narendra Lalwani and Steve Pinkosky to discuss our findings,… Read More
AHA 2014 Scientific Sessions: IMPROVE-IT Results Reported and What They Mean for the Future of ETC-1002
Last month, the American Heart Association (AHA) held its annual Scientific Sessions in Chicago, IL where presenters and attendees gathered from more than 105 countries to present cutting edge breakthroughs in cardiovascular science and research. Esperion colleagues have attended and participated in Scientific Sessions for many years and always look forward to seeing and hearing… Read More
October was a very big month for our company! Esperion not only announced positive top-line results from the ETC-1002-008 Phase 2b study in patients with hypercholesterolemia with or without statin intolerance, but within two weeks of this announcement we completed a successful follow-on public offering raising almost $100 million. October proved to be an exciting,… Read More
On July 29th, Esperion held its inaugural investor day in New York City, with a tightly-packed agenda for the half-day event that included presentations from several of the world’s leading experts in their respective fields. It was an exciting and informative day! Dr. James McKenney, President and CEO of National Clinical Research, and Professor Emeritus… Read More
Esperion recently relocated back to its Ann Arbor roots! Check out our newest video blog showcasing our colleagues hard at work, and the collaborative and innovative space we enjoy each day.
One year ago today the “new” Esperion re-entered the public markets with an initial public offering that raised $80 million and with a singular focus: to rapidly advance the development of ETC-1002, a unique, first-in-class, oral, once-daily low-density lipoprotein cholesterol (LDL-C) lowering therapy for patients with hypercholesterolemia who are unable to tolerate a statin. Since… Read More